{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'Procedures', 'Randomized Phase', 'Continuation', 'Phasec', 'Every 12', 'Weeks', '4', '12', '24', '36', '48b', '52', 'After', 'Week 52', 'PBMCsff', 'X', 'X', 'X', 'Xgg', 'Study Treatment', 'IVRS/IWRSh', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Dispense IP', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'IP accountability (pill counts)', 'X', 'X', 'X', 'X', 'X', 'ART - antiretroviral therapy, BMI - body mass index, CDC - centers for disease control and prevention, DNA - deoxyribonucleic acid, ECG - electrocardiogram, eCRF - electronic case', 'report form, HBV - hepatitis B virus, HCV - hepatitis C virus, INR - international normalized ratio, IP - investigational product', 'a.', 'As soon as all Screening results are available, randomization may occur.', 'b.', 'Participants with plasma HIV-1 RNA >50 c/mL at Week 48 (primary endpoint) must have HIV-1 RNA level re-assessed by a second measurement performed 2-4 weeks later,', 'occurring prior to Week 52.', 'C.', 'All participants on the DTG/3TC FDC arm who complete through Week 52 will have the opportunity to enter the Continuation Phase. The Continuation Phase is not applicable for', 'participants in Sweden and Denmark. For participants who will not continue past Week 52, do not dispense study intervention. Participants completing the Continuation Phase', 'must return to the clinic for an End of Continuation Phase visit when transitioning to commercial supplies or to an alternate ART regimen, if appropriate. At this visit, conduct study', 'assessments as specified for all Continuation Phase visits except for dispensing study intervention.', 'd.', 'An in-clinic Follow-Up visit will be conducted 4 weeks after the last dose of study intervention for participants with the following conditions at the last on-study visit: ongoing AEs,', 'serious adverse events (SAEs) regardless of attributability, and any laboratory abnormalities that are considered to be AEs or potentially harmful to the participant. However, the', 'investigator, in consultation with the medical monitor, should follow-up with the participant until the event is resolved, stabilized, otherwise explained, or the participant is lost to', 'follow-up', 'e.', 'Inclusion/exclusion criteria will be assessed fully at the Screening visit. Changes between the Screening visit and the Day 1 visit should be considered to ensure eligibility,', 'including review of additional assessments performed at Day 1. Genotypic resistance testing results if available MUST be provided to ViiV after screening and before', 'randomization.', 'f.', 'Full medical history will be conducted prior to randomization and include assessments of cardiovascular, metabolic (e.g., Type I or Il diabetes mellitus), psychiatric (e.g.,', 'depression), renal (e.g., nephrolithiasis, nephropathy, renal failure), and bone disorders.', 'g. Menopause history will include date of last menstrual period (collected at Day 1, Week 52 or withdrawal) and menopausal status (collected at Screening, Week 52 or withdrawal)', 'based on the criteria in Section 11.4.1. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.', '18']['2017N331008_06', 'CONFIDENTIAL', '208090', 'h.', 'Assessment for cardiovascular risk will include height, weight, blood pressure, smoking status and history, pertinent medical conditions (e.g., hypertension, diabetes mellitus), and', 'family history of premature cardiovascular disease. BMI will be calculated within the eCRF.', 'i.', 'The same scale should be used to measure body weight at each visit.', 'j.', \"Based on the participant's current CDC status in the past 6 months.\", 'k.', 'On Day 1, the electronic Columbia Suicidality Severity Rating Scale (eC-SSRS), participant completed questionnaire is to be administered prior to the first dose.', 'I.', 'Limited physical examination to include blood pressure at Day 1 (recorded in eCRF) for Framingham score assessment. Blood pressure to be measured after resting in a semi-', 'supine position for at least 5 minutes.', 'm.', 'A 12-lead ECG will be performed in a semi-supine position after resting for at least 5 minutes.', 'n.', 'Only SAEs related to study participation or to a concomitantly administered ViiV/GSK product will be collected between obtaining informed consent and administration of study', 'intervention at Day 1.', 'o. Willingness to Switch Survey must be done prior to randomization.', 'p.', 'Questionnaire/Surveys are recommended to be administered at the beginning of the visit before any other assessments are conducted. Only conduct questionnaires/surveys at', 'Withdrawal if occurring prior to Week 48, except the Symptom Distress Module which should also be collected if Withdrawal occurs during the Continuation Phase.', 'q.', 'See Virologic Withdrawal and Stopping Criteria Section of protocol (Section 7.1.1).', 'r.', 'Lymphocyte subset will include collection of CD4 and CD8 for calculation of Cd4:CD8 ratio. CD8 will also be reported to sponsor.', 'S.', 'Plasma samples for storage will be collected at each visit starting at Day 1, including unscheduled visits (e.g. for HIV-1 RNA levels and immunological parameters). These', 'samples will be used when needed such as when samples are lost, arrive at the laboratory unevaluable, or for genotypic and/or phenotypic analyses when participants meet', 'Suspected and Confirmed Virologic Withdrawal criteria.', 't.', 'See Appendix 7 for a list of clinical chemistry labs.', 'u.', 'An overnight fast is preferred; however, a minimum of a 6-hour fast is acceptable.', 'V.', 'Collect fasting lipids and glucose if the Withdrawal visit occurs at Weeks 24 or 48.', 'W. A morning specimen is preferred. To assess renal biomarkers: urine albumin/creatinine ratio; urine protein/creatinine ratio; and urine phosphate.', 'X.', 'Women of childbearing potential only. S=serum, U=urine. Pregnancy events will be captured starting at Day 1 following exposure to study intervention.', 'y.', \"Remind females of reproductive potential of the need to avoid pregnancy while in study and adherence to the study's contraception requirements.\", 'Z.', 'Local Pregnancy result must be available prior to randomization on Day 1. Local serum pregnancy test on Day 1 is allowed if it can be done, and results obtained, within', '24 hours prior to randomization.', 'aa. HBV DNA testing will be performed for participants with positive anti-HBc and negative HBsAg and negative anti-HBs (past and/or current evidence). Participants must return to', 'the clinic to provide a sample for HBV DNA testing prior to randomisation.', 'bb. Blood sample for HbA1c, insulin, glucose, renal, bone and inflammation biomarker assessments: Renal: Cystatin C, Beta-2-Microglobulin (urine), Retinol Binding Protein (RBP;', 'urine), urine B2M/creatinine ratio, urine RPB/creatinine ratio, urine albumin/creatinine ratio, urine protein/creatinine ratio, urine phosphate, serum creatinine; Bone: bone specific', 'alkaline phosphatase, procollagen type 1-N-propeptide, type 1 collagen cross-linked C-telopeptide, osteocalcin; Inflammation: Interleukin-6 (IL-6), High-sensitivity C reactive', 'protein (hs-CRP), D-dimer, Soluble CD14 (sCD14), Soluble CD163 (sCD163); insulin and glucose for HOMA-IR calculation', 'CC. Where local country or laboratory practices allow, whole blood (Virology) may be used for virologic analyses as described in the protocol.', 'dd. Where local country or laboratory practices allow, whole blood will be used for telomere length evaluation.', 'ee. Collect sample for these assessments ONLY if the Withdrawal visit occurs at Week 48.', 'ff.', 'Where local country or laboratory practices allow, PBMC collection samples may be used for virologic analyses as described in Section 8.10.1.', 'gg. Collect sample only if Withdrawal visit occurs at Weeks 24 or 48.', '19']\n\n###\n\n", "completion": "END"}